Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Secondary mutations of BRCA1/2 and drug resistance.

Dhillon KK, Swisher EM, Taniguchi T.

Cancer Sci. 2011 Apr;102(4):663-9. doi: 10.1111/j.1349-7006.2010.01840.x. Epub 2011 Jan 30. Review.

2.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T.

Nature. 2008 Feb 28;451(7182):1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.

3.

[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.

Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. Review. Polish.

4.
5.

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Wang W, Figg WD.

Cancer Biol Ther. 2008 Jul;7(7):1004-5. Review.

6.

Drug resistance caused by reversion mutation.

Ashworth A.

Cancer Res. 2008 Dec 15;68(24):10021-3. doi: 10.1158/0008-5472.CAN-08-2287. Review.

7.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

8.

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM.

J Clin Oncol. 2011 Aug 1;29(22):3008-15. doi: 10.1200/JCO.2010.34.2980. Epub 2011 Jun 27.

9.

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T.

Cancer Res. 2008 Apr 15;68(8):2581-6. doi: 10.1158/0008-5472.CAN-08-0088.

10.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985. Review.

PMID:
20140280
11.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

12.

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Bouwman P, Jonkers J.

Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Review.

13.

Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

Michalak EM, Jonkers J.

J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):41-50. doi: 10.1007/s10911-011-9199-z. Epub 2011 Feb 18. Review.

PMID:
21331759
14.

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.

Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.

BMC Cancer. 2014 Dec 19;14:983. doi: 10.1186/1471-2407-14-983.

15.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
16.

Opportunities and hurdles in the treatment of BRCA1-related breast cancer.

Drost R, Jonkers J.

Oncogene. 2014 Jul 17;33(29):3753-63. doi: 10.1038/onc.2013.329. Epub 2013 Aug 19. Review.

PMID:
23955079
17.

Targeting DNA repair in breast cancer: a clinical and translational update.

Amir E, Seruga B, Serrano R, Ocana A.

Cancer Treat Rev. 2010 Nov;36(7):557-65. doi: 10.1016/j.ctrv.2010.03.006. Epub 2010 Apr 10. Review.

PMID:
20385443
18.

Systemic therapy options in BRCA mutation-associated breast cancer.

Bayraktar S, Glück S.

Breast Cancer Res Treat. 2012 Sep;135(2):355-66. doi: 10.1007/s10549-012-2158-6. Epub 2012 Jul 12. Review.

PMID:
22791366
19.

PARP inhibitors in the management of breast cancer: current data and future prospects.

Livraghi L, Garber JE.

BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk